Many Investors Discouraged By Data From ASCO Meeting
Although the American Society of Clinical Oncology meeting in Orlando, Fla., which wrapped up last week, spewed much data and generated plenty of talk, the news wasn't all good for biotechnology firms, nor was it all bad. In a down market, however, the word "mixed" doesn't carry quite the cautious optimism it once did at least not for those with cash on the line. (BioWorld Financial Watch)
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.